There may be one or two dollars more in the bid but I think the price does reflect the business. If they had a fantastic product in late-stage testing, you'd offer more but you don't make a spectacular bid for a company that's not spectacular.

The jewels are the vaccines business and blood testing. There's nothing about Chiron that makes you say 'wow, we need to buy this for the pipeline.' The portfolio is rather lackluster compared to other biotechnology companies.

It's still the beginning, and the beginning is when you have to be tough.

It is a good marketing tool that the FDA has approved it, so I am quite sure they will make some inroads in the U.S. That is for sure.

Detroit, when it comes to the quick casual restaurant business, has done extremely well. When you look at the volume compared to other cities, Detroit is always on the top tier. You have a very strong workforce that tends to eat out every day.

There is a lot more to the processor business than selling processors. Controlling the supply chain and controlling product offerings is almost more important. And it's not just the supply chain, it's their manufacturing ability. They are way ahead in terms of manufacturing ability and economies of scale.